Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 11Dermatologic 6Thoracic 5CNS 4Sarcoma 3Other hematologic neoplasm 3Other solid neoplasm 2Genitourinary 2Lymphoid 1Gynecologic 1Breast 1

Conditions

Glioblastoma 3Glioma 2Uveal Melanoma 1Recurrence 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × ADI PEG20 × CNS × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT07389278 2026-02-05

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

University of California, San Francisco

Phase 1/2 Not yet recruiting
97 enrolled
CNS

Glioblastoma, Glioma

NCT04587830 2025-08-26

GBM

Polaris Group

Phase 2 Active not recruiting
100 enrolled
CNS

Glioblastoma

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡